{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"22.88","upperLimit":"168.00","value":"60.18"},{"groupId":"OG001","lowerLimit":"49.35","upperLimit":"167.88","value":"70.60"},{"groupId":"OG002","lowerLimit":"44.00","upperLimit":"168.50","value":"71.11"},{"groupId":"OG003","lowerLimit":"24.00","upperLimit":"190.95","value":"72.55"},{"groupId":"OG004","lowerLimit":"70.23","upperLimit":"169.30","value":"73.22"},{"groupId":"OG005","lowerLimit":"46.23","upperLimit":"173.50","value":"70.58"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"22"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"6"}],"units":"Participants"}],"title":"Cycle 1 Week 1"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.10","upperLimit":"70.40","value":"58.77"},{"groupId":"OG001","lowerLimit":"22.78","upperLimit":"168.57","value":"71.15"},{"groupId":"OG002","lowerLimit":"0","upperLimit":"167.00","value":"70.00"},{"groupId":"OG003","lowerLimit":"0.25","upperLimit":"172.53","value":"59.12"},{"groupId":"OG004","lowerLimit":"48.88","upperLimit":"165.12","value":"71.92"},{"groupId":"OG005","lowerLimit":"5.67","upperLimit":"70.85","value":"49.33"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"11"},{"groupId":"OG003","value":"16"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"6"}],"units":"Participants"}],"title":"Cycle 2 Week 1"}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"22"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"6"}],"units":"Participants"}],"dispersionType":"Full Range","groups":[{"description":"Mezagitamab 45 mg, SC, once weekly for 8 weeks, then once every 2 weeks for 16 weeks, and then once every 4 weeks thereafter in a 28-day treatment cycle until progressive disease (PD), unacceptable toxicities or withdrawal due to other reasons.","id":"OG000","title":"Phase 1 Dose Escalation Cohort: Mezagitamab 45 mg"},{"description":"Mezagitamab 135 mg, SC, once weekly for 8 weeks, then once every 2 weeks for 16 weeks, and then once every 4 weeks thereafter in a 28-day treatment cycle until PD, unacceptable toxicities or withdrawal due to other reasons.","id":"OG001","title":"Phase 1 Dose Escalation Cohort: Mezagitamab 135 mg"},{"description":"Mezagitamab 300 mg, SC, once weekly for 8 weeks, then once every 2 weeks for 16 weeks, and then once every 4 weeks thereafter in a 28-day treatment cycle until PD, unacceptable toxicities or withdrawal due to other reasons.","id":"OG002","title":"Phase 1 Dose Escalation Cohort: Mezagitamab 300 mg"},{"description":"Mezagitamab 600 mg, SC, once weekly for 8 weeks, then once every 2 weeks for 16 weeks, and then once every 4 weeks thereafter in a 28-day treatment cycle until PD, unacceptable toxicities or withdrawal due to other reasons.","id":"OG003","title":"Phase 1 Dose Escalation Cohort: Mezagitamab 600 mg"},{"description":"Mezagitamab 1200 mg, SC, once weekly for 8 weeks, then once every 2 weeks for 16 weeks, and then once every 4 weeks thereafter in a 28-day treatment cycle until PD, unacceptable toxicities or withdrawal due to other reasons.","id":"OG004","title":"Phase 1 Dose Escalation Cohort: Mezagitamab 1200 mg"},{"description":"Mezagitamab 300 mg, SC, once weekly for 8 weeks, then once every 2 weeks for 16 weeks, and then once every 4 weeks thereafter along with pomalidomide, at product-labelled dose, orally, once daily on Days 1 to 21 and dexamethasone, at product-labelled dose, orally, once on Days 1, 8, 15, and 22 in a 28-day treatment cycle until PD.","id":"OG005","title":"Phase 1 Combination Cohort: Mezagitamab 300 mg + PomDex"}],"paramType":"MEDIAN","populationDescription":"PK analysis set included those participants from the safety analysis set who had sufficient dosing data and mezagitamab concentration-time data to permit the calculation of PK parameters. Number analyzed is the number of participants with data available for analysis at the given timepoint.","reportingStatus":"POSTED","timeFrame":"Cycles 1 and 2: Day 1 pre-dose and at multiple time points (up to 190.95 hours) post-dose (cycle length=28 days)","title":"Tmax: Time to Reach the Maximum Observed Serum Concentration (Cmax) for TAK-079","type":"SECONDARY","unitOfMeasure":"hours (h)"}